DNA damage responses and chemosensitivity in the Eμ-myc mouse lymphoma model

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 65, Issue , 2000, Pages 499-510

  Schmitt, C A ^a   Wallace Brodeur, R R ^a   Rosenthal, C T ^a   McCurrach, M E ^a   Lowe, S W ^a  

^a Watson School of Biological Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; OXAZAPHOSPHORINE; PROTEIN P53; GYRASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER THERAPY; CHEMOSENSITIVITY; CLONOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; EXPERIMENTAL NEOPLASM; GENETIC TRANSDUCTION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; ARTICLE; DISEASE MODEL; DRUG RESISTANCE; GENETICS; HUMAN; MOUSE MUTANT; NUTRITIONAL DEFICIENCY; ONCOGENE MYC; ANIMAL TISSUE; APOPTOSIS; CANCER MODEL; CANCER RESISTANCE; DNA DAMAGE RESPONSE; MOUSE MODEL; TREATMENT RESPONSE;

ANIMALIA; DROMAIUS NOVAEHOLLANDIAE; MUS MUSCULUS;

ANIMAL; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENES, MYC; HUMAN; LYMPHOMA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTEIN P53; SUPPORT, NON-U.S. GOV'T;

EID: 0034437946     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2000.65.499     Document Type: Conference Paper

References (41)

1. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
2. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
3. Autochthonous tumor models in rats: Is there still a relevance for anticancer drug development?
4. Transplantable tumours in mice - The way forward
5. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
6. ARF tumor suppressor
7. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts
8. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression
9. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells
10. Human tumor xenografts: Predictivity, characterization and discovery of new anticancer agents
11. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias
12. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors
13. The Eμ-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells
14. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic
15. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis
16. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
17. Effects of an Rb mutation in the mouse
18. Tumor spectrum analysis in p53-mutant mice
19. Participation of p53 protein in the cellular response to DNA damage
20. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis
21. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells
22. Cleavage of poly(ADR-ribose) polymerase by a proteinase with properties like ICE
23. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival
24. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
25. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma
26. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas
27. Mouse mammary tumor virus-ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: Protein transferase inhibitor
28. Derivatives of Moloney murine sarcoma virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional SP1 binding site
29. Utilization of genetically altered animals in the pharmaceutical industry
30. Apoptosis and therapy
31. Genetic analysis of chemoresistance in primary murine lymphomas
32. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
33. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p161NK4a
34. Role of the INK4a locus in tumor suppression and cell mortality
35. Tumor surveillance via the ARF-p53 pathway
36. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells
37. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
38. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
39. The apoptosis endonuclease and its regulation
40. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
41. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization